| Identification | More | [Name]
Anastrozole | [CAS]
120511-73-1 | [Synonyms]
1-[3,5-DI-(1-METHYL-1-CYANO)-ETHYL]-BENZYL-1,2,4-TRIAZOLE
ANASTRAZOLE
ANASTROZOLE
ARIMIDEX
ICI-D-1033
tetramethyl-5-(1h-1,2,4-triazol-1ylmethyl) 1,3-benzenediacetionitrile
ZD-1033
1,3-benzenediacetonitrile,alpha,alpha,alpha’,alpha’-tetramethyl-5-(1h-1,2,4-t
riazol-1-ylmethyl)-
Anastrozol
Anatrozole
ZD-1033, ICI-D-1033, Arimidex
2-[3-(2-Cyano-2-propyl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropiononitrile
1,3-benzenediacetonitrile, alpha,alpha,alpha',alpha'-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-
zd
a1,a1,a3,a3-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile
Anastrol
α，α，α’，α'-Tetramethyl-5-(1H-1，2，4-triazol-1-ylmethyl)-1，3-benzenediacetonitrile
2-[3-(2-Cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile | [EINECS(EC#)]
601-715-6 | [Molecular Formula]
C17H19N5 | [MDL Number]
MFCD00866298 | [Molecular Weight]
293.37 | [MOL File]
120511-73-1.mol |
| Chemical Properties | Back Directory | [Appearance]
Crystalline Solid | [Melting point ]
81-82°C | [Boiling point ]
469.7±55.0 °C(Predicted) | [density ]
1.08±0.1 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
DMSO: soluble40mg/mL | [form ]
solid | [pka]
2.62±0.10(Predicted) | [color ]
White to off-white | [Usage]
An aromatase inhibitor. Used as an antineoplastic. | [BCS Class]
1 (LogP),
3 (CLogP) | [InChI]
InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3 | [InChIKey]
YBBLVLTVTVSKRW-UHFFFAOYSA-N | [SMILES]
C(#N)C(C1=CC(CN2C=NC=N2)=CC(C(C#N)(C)C)=C1)(C)C | [CAS DataBase Reference]
120511-73-1(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S37/39:Wear suitable gloves and eye/face protection . | [RIDADR ]
3249 | [WGK Germany ]
3 | [RTECS ]
CZ1465000 | [HazardClass ]
6.1(b) | [PackingGroup ]
III | [HS Code ]
29339900 | [Hazardous Substances Data]
120511-73-1(Hazardous Substances Data) |
| Questions And Answer | Back Directory | [Description]
Anastrozole (120511-73-1), chemically known as 2,2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropiononitrile) a derivative of benzotriazole with the CAS registry number 120511-73-1, is a non-steroidal, third-generation achiral triazole derivative marketed as ARIMIDEX? by AstraZeneca Pharmaceuticals LP1. It is one of the third-generation aromatase inhibitor which is a highly competitive and selective inhibitor of aromatase, thus blocking the conversion of testosterone into estradiol and androstenedione into estrone. Inhibition of the aromatase enzyme occurs particularly through competitive binding of aromatase to the hemegroup of cytochrome P450, decreasing estrogen biosynthesis in the peripheral tissues of the body and in the breast.
| [Treatment for Early-stage Breast Cancer]
Anastrozole is a generally well tolerated treatment for early-stage breast cancer. Like other aromatase inhibitors, its most important adverse effect was an increased risk of bone fractures, which for anastrozole was restricted to the treatment period. It characteristically has mild toxicity when compared with chemotherapy; however, it have been noticed that more patients treated with anastrozole have complained of joint symptoms than expected, particularly digital stiffness similar to that of rheumatoid arthritis. Some clinical trials of anastrozole for postmenopausal women with breast cancer in Europe and the United states reported musculoskeletal disorders as adverse events.
Anastrozole (Arimidex®) is an aromatase inhibitor approved in the EU, the US and in other countries worldwide for use as an adjuvant treatment in postmenopausal women with early-stage, hormone receptor-positive breast cancer. It is also approved in the EU and other countries worldwide for continuing adjuvant treatment in women who have already had 2–3 years of adjuvant tamoxifen treatment for breast cancer. | [Uses]
Anastrozole has significant effects on breast cancer treatment and, therefore, it is currently used as first-line treatment in estrogen receptor (ER)-positive postmenopausal women, particularly to treat locally advanced or metastatic breast cancer. Furthermore, it is also indicated for early cancer treatment, tumor chemoprevention and postmenopausal women using tamoxifen, especially if the drug is used during a prolonged period of time and has been indicated in the disease’s recurrence, i.e., as another therapeutic endocrine option.
| [Pharmacokinetics]
Anastrozole has linear pharmacokinetics. It is metabolized primarily in the liver, with a plasma elimination half-life of 40–50 hours, indicating that oncedaily administration is adequate. In vitro and clinical studies indicate that drugdrug interactions are unlikely to occur between anastrozole and drugs metabolized by hepatic cytochrome P450 enzymes. In patients with breast cancer, there were no clinically important interactions between anastrozole and tamoxifen or its metabolite, N-desmethyltamoxifen.
| [Indications and Usage]
Anastrozole(120511-73-1) is a potent selective triazole aromatase inhibitor that inhibits the aromatase that cytochrome P-450 is dependent on to prevent the biosynthesis of estrogen. Estrogen is the main stimulating factor for breast cancer cell growth. This drug’s half maximal inhibitory concentration (IC50) value to human placental aromatase is 15nmol/L. Compared to the traditional drug tamoxifen, Anastrozole can comprehensively and effectively lower the risks of breast cancer recurrence and metastasis, thus extending patients’ disease-free survival.
Anastrozole is suitable for treating postmenopausal advanced breast cancer patients, especially postmenopausal advanced breast cancer patients who experienced recurrence following hormone assisted therapy.
| [Clinical Research]
A series of clinical trials compared the effects of third generation aromatase inhibitor Anastrozole with those of tamoxifen. The trial was a global multicenter trial and includes 381 centers in 21 countries. Since 1996, there have been 9366 patients who have participated, and the follow-up time is 100 months. 25.8% of patients in the Anastrozole group experienced recurrence, while 29.9% of patients in the tamoxifen group did. Thus, Anastrozole’s recurrence rate was 4.1% lower than that of tamoxifen, and its risk of distant metastasis was lower as well. Anastrozole is also safer than tamoxifen.
|
| Hazard Information | Back Directory | [Chemical Properties]
Crystalline Solid. soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of anastrozole in these solvents is approximately 20, 13, and 14 mg/ml.
| [Originator]
Zeneca (United Kingdom) | [Application]
Anastrozole (aromatase inhibitor) has been used:
as a positive control in DNA fragmentation (ladder) assay
to investigate its effects along with extra virgin olive oil and its major fatty acid component (omega-9 OA) in estrogen receptor positive mammary adenocarcinoma cells
to study its effects on viability, cell proliferation and apoptosis in Glioblastoma multiforme model in vivo | [Definition]
ChEBI: Anastrozole(120511-73-1) is a 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position. It has a role as an antineoplastic agent and an EC 1.14.14.14 (aromatase) inhibitor. It is a member of triazoles and a nitrile. | [Preparation]
synthesis of anastrozole can be realized in four steps based on 3,5-bis(bromomethyl)toluene. Starting with a S N 2 displacement using potassium nitrile and tetrabutylammonium bromide as a phase transfer catalyst to give bis-nitrile compound. Bis-nitrile compound formed undergoes deprotonation with NaH and methylated afterwards with methyl iodide to give bis-dimethyated product.Product undergoes radical substitution reaction following the Wohl-Ziegler reaction using N-bromosuccinamide and benzoyl peroxide as the radical initiator.In the final step, benzylbromide undergoes SN2 displacement with sodium triazole to give anastrozole.
 | [Manufacturing Process]
A mixture of 2,2-(5-methyl-1,3-phenylene)di(2-methylpropionitrile) (2.26 g),
N-bromosuccinimide (1.78 g), benzoylperoxide (0.05 g) and carbon
tetrachloride (50 ml) was refluxed for 2 hours, cooled and filtered, and the
filtrate was evaporated to dryness under reduced pressure. The residue was
dissolved in dimethylformamide (20 ml), sodium triazole (1.8 g) was added,
and the mixture was stirred at room temperature for 18 h. Water (100 ml)
was added, and the mixture was extracted twice with ethyl acetate, dried and
evaporated to dryness and the residue was purified by flash column
chromatography, eluting with ethyl acetate to give 2,2-[5-(1H-1,2,4-triazol-1-
ylmethyl)-1,3-phenylene]di(2-methylpropionitrile), mp 81-82°C after
crystallization from ethyl acetate/cyclohexane.
The 5-methyl-1,3-phenylene compound used as starting material in above
process may be prepared as follows. The mixture of 3,5-
bis(bromomethyl)toluene (30 g), tetrabutyl-ammonium bromide (1 g), KCN
(17.6 g), dichloromethane (100 ml) and water (30 ml) was stirred vigorously
and refluxed for 3 h. The mixture was cooled, diluted with water (100 ml) and
extracted three times with ethyl acetate, dried and evaporated to dryness, the
residue was purified by flash chromatography, eluting with petroleum
ether/ethyl acetate (3:1) to give 2,2-(5-methyl-1,3-phenylene)diacetonitrile,
mp 73-74°C after crystallization from carbon tetrachloride. A mixture of this
diacetonitrile (11.5 g), iodomethane (42 g) and dimethylformamide (150 ml)
was cooled in an ice and stirred while sodium hydride (50% dispersion in
mineral oil, 15 g) was added slowly, over 1 hour, then the mixture was
allowed to warm to room temperature, stirred for 2 h, 500 ml of water was
added, and the mixture was extracted twice with ethyl acetate, the extracts
were dried and evaporated to dryness and the residue was crystallized from
carbon tetrachloride to give the required 5-methyl-1,3-phenylene starting material, mp 126-127°C. | [Brand name]
Arimidex
(AstraZeneca). | [Therapeutic Function]
Antitumor | [General Description]
Anastrozole,α,α,α',α'-tetramethyl5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile,was the first specific aromatase inhibitor approved in theUnited States. It is indicated for first-line treatment of postmenopausalwomen with advanced or metastatic breast cancer,for second-line treatment of postmenopausal patientswith advanced breast cancer who have had disease progressionfollowing tamoxifen therapy, and for adjuvant treatmentof women with early breast cancer. Patients who did not respondto tamoxifen therapy rarely respond to anastrozole. | [Biological Activity]
Potent and highly selective aromatase (CYP19) inhibitor (IC 50 = 15nM) that has no discernible effect on adrenocorticoid hormone synthesis. Reduces plasma estrogen levels and exhibits antitumor activity in vivo . Orally active. | [Biochem/physiol Actions]
Anastrozole, which contains a triazole functional group, reversibly binds to the cytochrome P-450 component of aromatase. Binding interferes with the catalytic properties of aromatase, which results in inhibition of estrogen synthesis. | [Mechanism of action]
Anastrozole, a benzyltriazole derivative, competes with the natural s ubstrate for binding to the active site of the aromatase. The mechanism of enzyme inhibition resides in the coordination of the triazole ring with the hemeiron atom of the aromatase enzyme complex. This coordination ultimately prevents arom atization of androgens into estrogens and, therefore, deprives the tumor of estrogen. This effect is reversible. In the presence of anastrozole, estradiol levels are reduced to undetectable levels, with no adverse effects on levels of any other horm one, including cortisol and aldosterone. | [Clinical Use]
Anastrozole is a potent and highly selective, nonsteroidal aromatase inhibitor utilized in the treatment of advanced breast cancer that is horm one-responsive. It is considered to be second-line therapy (after tamoxifen) in the treatment of postm enopaus al breast cancer. | [Side effects]
The most common anastrozole side effects are related to lower estrogen levels in the body. They include hot flashes, nausea and vomiting, and mood changes. Anastrozole could cause your bones to thin, which raises your risk of osteoporosis. It can also cause high cholesterol. | [Drug interactions]
Potentially hazardous interactions with other drugs
Oestrogen-containing therapies: avoid concomitant
administration as would negate pharmacological
action.
Tamoxifen: avoid concomitant administration. | [Environmental Fate]
Anastrozole is classified as readily biodegradable and is moderately mobile in soils. The measured octanol-water partition coefficient is low, therefore anastrozole is not predicted to bioaccumulate in aquatic organisms. | [Metabolism]
Anastrozole is extensively metabolised by postmenopausal
women with less than 10% of the dose excreted in the
urine unchanged within 72 hours of dosing. Metabolism
of anastrozole occurs by N-dealkylation, hydroxylation
and glucuronidation via CYP 3A4 and 3A5, and
UGT1A4. The metabolites are excreted primarily via the
urine. Triazole, the major metabolite in plasma, does not
inhibit aromatase. | [storage]
Store at -20°C | [References]
[1] DUKESM. The preclinical pharmacology of “Arimidex” (anastrozole; ZD1033)–a potent, selective aromatase inhibitor.[J]. Journal of Steroid Biochemistry and Molecular Biology, 1996. DOI:10.1016/0960-0760(96)00064-7.
[2] U B. Anastrozole: a new addition to the armamentarium against advanced breast cancer.[J]. American Journal of Clinical Oncology-Cancer Clinical Trials, 1998. DOI:10.1097/00000421-199804000-00014.
[3] L?NNINGP E DowsettM GeislerJ. Pharmacological and clinical profile of anastrozole.[J]. Breast Cancer Research and Treatment, 1998. DOI:10.1023/a:1006000806630.
[4] HOZUMIYASUO. Effects of anastrozole on lipid metabolism compared with tamoxifen in rats.[J]. Breast Cancer Research and Treatment, 2002. DOI:10.1023/a:1020571617274. |
|
|